This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sun, X. Articles by Kang, Y. J. Search for Related Content PubMed PubMed Citation Articles by Sun, X. Articles by Kang, Y. J.

Attenuation of Doxorubicin Chronic Toxicity in Metallothionein-overexpressing Transgenic Mouse Heart¹

Departments of Medicine, and Pharmacology and Toxicology, University of Louisville, School of Medicine, [X. S., Z. Z., Y. J. K.], and Jewish Hospital Heart and Lung Institute [Y. J. K.], Louisville, Kentucky 40202

Previous studies have shown that cardiac-specific metallothionein (MT)-overexpressing transgenic mice are highly resistant to acute cardiotoxicity induced by doxorubicin (DOX), a most effective anticancer agent. However, cumulative dose-dependent chronic cardiotoxicity attributable to long-term administration of DOX is a significant clinical problem. Because MT is a potent antioxidant and oxidative stress is critically involved in DOX-induced heart injury, the present study was undertaken to test the hypothesis that MT also provides protection against DOX chronic cardiotoxicity. Transgenic mice containing high levels of cardiac MT and nontransgenic controls were treated with a cumulative dose of 40 mg/kg of DOX in 10 equal i.v. injections over a period of 7 weeks. Three weeks after the last injection, the mice were killed for an analysis of cardiotoxicity. As compared with nontransgenic controls, DOX-induced cardiac hypertrophy was significantly inhibited in the transgenic mice. Light microscopic examination revealed that DOX-induced myocardial morphological changes were markedly suppressed or almost eliminated in the transgenic mice. Under electron microscopy, extensive sarcoplasmic vacuolization and severe disruption of mitochondrial fine structure were observed in nontransgenic cardiomyocytes, but almost no sarcoplasmic vacuolization was observed, and the mitochondrial structural changes were almost completely prevented in the transgenic cardiomyocytes. The results thus indicate that MT elevation is a highly effective approach to prevent chronic cardiomyopathy attributable to DOX. This study also suggests that oxidative stress is critically involved in the DOX-induced chronic cardiotoxicity.

This article has been cited by other articles:

				J. Niu, A. Azfer, K. Wang, X. Wang, and P. E. Kolattukudy Cardiac-Targeted Expression of Soluble Fas Attenuates Doxorubicin-Induced Cardiotoxicity in Mice J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 740 - 748. [Abstract] [Full Text] [PDF]

				K. Y. Wonders, D. S. Hydock, C. M. Schneider, and R. Hayward Acute Exercise Protects Against Doxorubicin Cardiotoxicity Integr Cancer Ther, September 1, 2008; 7(3): 147 - 154. [Abstract] [PDF]

				E. Grasselli, L. Canesi, A. Voci, R. De Matteis, I. Demori, E. Fugassa, and L. Vergani Effects of 3,5-Diiodo-L-Thyronine Administration on the Liver of High Fat Diet-Fed Rats Experimental Biology and Medicine, May 1, 2008; 233(5): 549 - 557. [Abstract] [Full Text] [PDF]

				D. Frank, C. Kuhn, B. Brors, C. Hanselmann, M. Ludde, H. A. Katus, and N. Frey Gene Expression Pattern in Biomechanically Stretched Cardiomyocytes: Evidence for a Stretch-Specific Gene Program Hypertension, February 1, 2008; 51(2): 309 - 318. [Abstract] [Full Text] [PDF]

				S. Deng, B. Kulle, M. Hosseini, G. Schluter, G. Hasenfuss, L. Wojnowski, and A. Schmidt Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity Eur J Heart Fail, October 1, 2007; 9(10): 986 - 994. [Abstract] [Full Text] [PDF]

				Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues Mol. Interv., June 1, 2007; 7(3): 147 - 156. [Abstract] [Full Text] [PDF]

				K. E. Merten, Y. Jiang, and Y. J. Kang Zinc Inhibits Doxorubicin-Activated Calcineurin Signal Transduction Pathway in H9c2 Embryonic Rat Cardiac Cells Experimental Biology and Medicine, May 1, 2007; 232(5): 682 - 689. [Abstract] [Full Text] [PDF]

				C. Ojaimi, K. Qanud, T. H. Hintze, and F. A. Recchia Altered expression of a limited number of genes contributes to cardiac decompensation during chronic ventricular tachypacing in dogs Physiol Genomics, March 14, 2007; 29(1): 76 - 83. [Abstract] [Full Text] [PDF]

				K. E. Merten, Y. Jiang, W. Feng, and Y. J. Kang Calcineurin Activation Is Not Necessary for Doxorubicin-Induced Hypertrophy in H9c2 Embryonic Rat Cardiac Cells: Involvement of the Phosphoinositide 3-Kinase-Akt Pathway J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 934 - 940. [Abstract] [Full Text] [PDF]

				Y. J. Kang Metallothionein redox cycle and function. Experimental Biology and Medicine, October 1, 2006; 231(9): 1459 - 1467. [Abstract] [Full Text] [PDF]

				J. Wang, Y. Song, L. Elsherif, Z. Song, G. Zhou, S. D. Prabhu, J. T. Saari, and L. Cai Cardiac Metallothionein Induction Plays the Major Role in the Prevention of Diabetic Cardiomyopathy by Zinc Supplementation Circulation, January 31, 2006; 113(4): 544 - 554. [Abstract] [Full Text] [PDF]

				W. Feng, F. W. Benz, J. Cai, W. M. Pierce, and Y. J. Kang Metallothionein Disulfides Are Present in Metallothionein-overexpressing Transgenic Mouse Heart and Increase under Conditions of Oxidative Stress J. Biol. Chem., January 13, 2006; 281(2): 681 - 687. [Abstract] [Full Text] [PDF]

				K. E. Merten, W. Feng, L. Zhang, W. Pierce, J. Cai, J. B. Klein, and Y. J. Kang Modulation of Cytochrome c Oxidase-Va Is Possibly Involved in Metallothionein Protection from Doxorubicin Cardiotoxicity J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1314 - 1319. [Abstract] [Full Text] [PDF]

				L. Xie, G. Tsaprailis, and Q. M. Chen Proteomic Identification of Insulin-like Growth Factor-binding Protein-6 Induced by Sublethal H2O2 Stress from Human Diploid Fibroblasts Mol. Cell. Proteomics, September 1, 2005; 4(9): 1273 - 1283. [Abstract] [Full Text] [PDF]

				L. Wang, Z. Zhou, J. T. Saari, and Y. J. Kang Alcohol-Induced Myocardial Fibrosis in Metallothionein-Null Mice: Prevention by Zinc Supplementation Am. J. Pathol., August 1, 2005; 167(2): 337 - 344. [Abstract] [Full Text] [PDF]

				Q. M. Chen, D. Alexander, H. Sun, L. Xie, Y. Lin, J. Terrand, S. Morrissy, and S. Purdom Corticosteroids Inhibit Cell Death Induced by Doxorubicin in Cardiomyocytes: Induction of Antiapoptosis, Antioxidant, and Detoxification Genes Mol. Pharmacol., June 1, 2005; 67(6): 1861 - 1873. [Abstract] [Full Text] [PDF]

				M. Kannan, L. Wang, and Y. J. Kang Myocardial Oxidative Stress and Toxicity Induced by Acute Ethanol Exposure in Mice Experimental Biology and Medicine, June 1, 2004; 229(6): 553 - 559. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				Y. J. Kang, Y. Li, X. Sun, and X. Sun Antiapoptotic Effect and Inhibition of Ischemia/Reperfusion-Induced Myocardial Injury in Metallothionein-Overexpressing Transgenic Mice Am. J. Pathol., October 1, 2003; 163(4): 1579 - 1586. [Abstract] [Full Text] [PDF]

				X. Sun and Y. J. Kang Prior Increase in Metallothionein Levels Is Required to Prevent Doxorubicin Cardiotoxicity Experimental Biology and Medicine, September 1, 2002; 227(8): 652 - 657. [Abstract] [Full Text] [PDF]

				Z. Zhou, X. Sun, J. C. Lambert, J. T. Saari, and Y. J. Kang Metallothionein-Independent Zinc Protection from Alcoholic Liver Injury Am. J. Pathol., June 1, 2002; 160(6): 2267 - 2274. [Abstract] [Full Text] [PDF]

				V. C. Tu, J. J. Bahl, and Q. M. Chen Signals of Oxidant-Induced Cardiomyocyte Hypertrophy: Key Activation of p70 S6 Kinase-1 and Phosphoinositide 3-Kinase J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1101 - 1110. [Abstract] [Full Text] [PDF]